HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
INSIDE INDUSTRY
Medicago awarded contract from the U.S. Department of Defence
Medicago Inc. announced that it has been awarded an Indefinite Delivery / Indefinite Quantity (ID/IQ) contract from the Defense Advanced Research Projects Agency (DARPA) based on Medicago having met all the technical requirement standards for the contract. As a result of Medicago having met these requirements and standards, the company is now allowed to bid for the manufacture and delivery of certain tobacco-produced proteins, for which Medicago has already demonstrated a proven ability. The company intends to bid on these orders when solicitations are next issued by the U.S. government and may be awarded production contracts.

“This contract is important as Medicago is now listed as a company meeting all of DARPA's rigorous technical requirements,” said Mike Wanner, Executive Vice President of Operations at Medicago. “This fits Medicago's revenue-generation model nicely as we can leverage our cost-effective commercial production facility in North Carolina to bid for production orders when they are issued by the U.S. government.”

Medicago USA, Inc. was previously awarded a US$21 million non-dilutive Technology Investment Agreement with DARPA for a proof of concept demonstration to produce 10 million doses of a vaccine candidate in 30 days.  The DARPA project was successfully completed, for which Medicago USA Inc. successfully completed every milestone including the production of more than 10 million doses of immunogenic vaccine in less than 30 calendar days as qualified by animal studies.

Medicago's pipeline includes a number of clinical trials for 2013 including: the initiation of a U.S. Phase IIa clinical trial for a quadrivalent seasonal flu vaccine with interim data expected in summer of 2013; a Phase I clinical trial for an H5N1 VLP vaccine with a new adjuvant that is ongoing in partnership with the Infectious Disease Research Institute (IDRI).  Interim data are expected in the first quarter of 2013 and a new clinical trial of the H5N1 VLP vaccine designed to determine the lowest possible dose by two different administration routes (IM and ID) and combining the vaccine with a GLA adjuvant is planned to start in spring of 2013, with interim data expected in summer of 2013.

Along with clinical trials, Medicago will be continuing their GMP process development and a GLP toxicology study for a rabies vaccine. The company is also working with Mitsubishi Tanabe Pharma under a strategic alliance to develop a vaccine for rotavirus and at least two additional vaccine candidates and in addition to vaccines; Medicago is conducting research and development in the area of biosimilar products.

Click here for the complete issue.

NEWS CRUNCH  
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
news World Immunisation Week 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy